EndoTool Glucose Management System | Clinical Decision Support for Insulin Dosing


A healthcare crisis must be addressed efficiently and effectively when time matters most.  Many technologies may be an asset in less demanding settings, but critical conditions pose different demands.

The American Diabetes Association (ADA) calls for continuous infusion of regular insulin as a key intervention during a diabetic crisis. A growing body of research is proving the effectiveness of EndoTool in precisely controlling glucose levels for a broad range of patient populations. But is it safe and effective for critically ill patients with a hyperglycemic crisis? Little research has focused on the issue, but that research is worth the read.

In January of this year, researchers at Tampa General Hospital conducted a study to determine the impact of the EndoTool system in lowering blood glucose levels appropriately in diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic (HHS) patients while minimizing any resulting hypoglycemia or severe hypoglycemia. ADA guidelines call for reducing blood glucose as much as 50 to 75 mg per hour.

Of the 50 patients included in the study, 44 had a diagnosis of DKA and six had a diagnosis of  HHS. Using EndoTool, the mean blood glucose reduction was 87 mg/dl per hour. A blood glucose reduction of at least 50 mg/dl per hour was achieved in 84% of the patients.

Let the numbers speak for themselves.